IRCT20201202049568N2招募中未知
Evaluation of safety and efficacy of allogeneic adipose-derived mesenchymal stem cell administration in Bronchiolitis Obliterans Syndrome (BOS) after allogeneic hematopoietic stem cell transplantation.
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 1 month 至 16 years（—）
- 性别
- All
入选标准
- •Age below 16 years
- •Allogeneic hematopoietic stem cell transplantation (HSCT) over the past year
- •Forced Expiratory Volume in one second (FEV1) < 70 % (based on Pulmonary Function Test)
- •Diagnosis of BOS in end-stage phase with the history and clinical evaluation by a pediatric pulmonologist, and the presence of air-trapping or small airway involvement in high-resolution computed tomography (HRCT)
- •Absence of concomitant infections
- •Irresponsible to full-dose corticosteroids
- •Give the informed consent by the patients' legal guardians
排除标准
- •Suspicion to any bacterial or viral pneumonia
- •CMV, VZV, HSV and/or fungal pneumonia
- •Haploidentical and/or T-cell deplete transplantation
- •Prior history of allergy or sensitivity to drugs
- •Relapse or progression of underlying malignancy
研究者
相似试验
招募中
2 期
Effect of treatmen with natural killer cells in acute myeloid leukemiaAcute myeloblastic leukemiaAcute Myeloid leukemia.C92.0IRCT20200417047113N2Middle East Gene Therapy corporation5
已完成
1 期
Effect of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cell Transplantation on SLESevere and Refractory Lupus Nephritis.Systemic lupus erythematosus with organ or system involvementIRCT2016090729747N1Council for Stem Cell Sciences and Technologies20
招募中
1 期
Effect of NK cell therapy in COVID-19IRCT20200417047113N1Middle East Gene Therapy corporation70
招募中
1 期
Evaluation of the safety and efficacy of allogeneic activated Natural killer cells in metastatic Colon AdenocarcinomaIRCT20230704058675N1Middle East Gene Therapy corporation10
已完成
1 期
Evaluation of the safety and efficacy of allogeneic hematopoietic stem cell transplantation (HSCT) using alemtuzumab for patients with aplastic anemiaAplastic anemiaJPRN-C000000356GCP-ISS HE0403 group38